The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

The bladder cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

Combining reduced-dose olaparib with radium-223 improved rPFS in mCRPC patients, especially those without prior docetaxel and limited bone metastases. The combination's efficacy is based on mechanisms ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 4-5 in opposition of a favorable benefit-risk profile for UGN-102 (mitomycin) intravesical solution in adult patients with recurrent low-grade ...

The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.

The AUSCO trial showed a 94% success rate in achieving significant continence improvement in men with SUI using the artificial urinary sphincter. The study found no device infections and low ...

One of many notable highlights from the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada was the release of the “Genitourinary Syndrome of Menopause: AUA/SUFU [Society of ...